TGX Trademark

Trademark Overview


On Friday, January 31, 2025, a trademark application was filed for TGX with the United States Patent and Trademark Office. The USPTO has given the TGX trademark a serial number of 79421844. The federal status of this trademark filing is FINAL REFUSAL - MAILED as of Sunday, April 19, 2026. This trademark is owned by Trogenix Ltd. The TGX trademark is filed in the Pharmaceutical Products and Computer & Software Products & Electrical & Scientific Products categories with the following description:

Downloadable computer software programs for use in laboratory management systems and gene therapy platforms; downloadable software, namely, software for use with lab information management systems; downloadable computer software platforms for medical and scientific research; downloadable software for remote diagnostics; downloadable software using machine learning for analysing genomic data, designing gene therapy solutions and to assist with drug development; downloadable software using machine learning for use in genetic sequencing; algorithms, being computer software for use in designing genetic medicines and cancer immunotherapies; downloadable bioinformatics software; imaging apparatus and instruments for use in the study of proteins and peptides in drug development; downloadable data processing software; downloadable computer applications for use in the fields of oncology, recombinant protein production, immunology, cell engineering, viral vector engineering, genetic engineering,...

Pharmaceutical, medical or veterinary preparations and substances for the treatment of oncological diseases, genetic diseases, fibrosis and degenerative diseases; pharmaceutical preparations for use in targeted pharmaceutical therapies for the treatment of oncological diseases, genetic diseases, fibrosis and degenerative diseases; pharmaceutical preparations and anti-neoplastic products for the treatment of neoplastic diseases; pharmaceutical preparations for the treatment of carcinomas and leukaemias; pharmaceutical preparations for the treatment of central nervous system tumours, glioblastoma, colorectal liver metastasis, squamous cell carcinomas, pancreatic cancer, melanoma, breast cancer hepatocellular carcinoma and metastatic tumours; enhancers or super-enhancers for medical or clinical use; engineered DNA as synthetic super enhancers in gene expression cassettes for medical or clinical use; DNA sequences for medical purposes; pharmaceutical preparations for use in regenerative me...
tgx

General Information


Serial Number79421844
Word MarkTGX
Filing DateFriday, January 31, 2025
Status645 - FINAL REFUSAL - MAILED
Status DateSunday, April 19, 2026
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateNOT AVAILABLE

Trademark Statements


Goods and ServicesDownloadable computer software programs for use in laboratory management systems and gene therapy platforms; downloadable software, namely, software for use with lab information management systems; downloadable computer software platforms for medical and scientific research; downloadable software for remote diagnostics; downloadable software using machine learning for analysing genomic data, designing gene therapy solutions and to assist with drug development; downloadable software using machine learning for use in genetic sequencing; algorithms, being computer software for use in designing genetic medicines and cancer immunotherapies; downloadable bioinformatics software; imaging apparatus and instruments for use in the study of proteins and peptides in drug development; downloadable data processing software; downloadable computer applications for use in the fields of oncology, recombinant protein production, immunology, cell engineering, viral vector engineering, genetic engineering, biopharmaceuticals, molecular biology, modulating therapeutics, assay systems, antigens and in vitro assays; downloadable software for predicting protein expression; downloadable software in the fields of genomes, genetic mapping, molecular genetics, gene regulation, molecular biology, microbiology, pharmaceuticals, medicine, diagnostic preparations, vaccines, medicine, health, microorganisms, molecular sciences, bacteria, biochemicals, cells, stem cells, clinical trials, physiology, genetics, genomics, microbiome, metabolomics, metagenomics, proteomics, glycomics, biochemistry, therapeutics, targeted pharmaceutical therapies, bacteriology, gene expression, DNA sequencing, DNA screening, biochemical reagents and biochemical assays; downloadable computer software for scientific analysis of genetic sequences; downloadable software for creating optimization algorithms in the fields of biotechnology and modulating therapeutics; software as a medical device (SAMD), for prevention, diagnosis, treatment, and monitoring of oncological diseases, genetic diseases, fibrosis and degenerative diseases; downloadable software using artificial intelligence for use in oncological, genetic and degenerative healthcare and in relation to fibrosis
Goods and ServicesPharmaceutical, medical or veterinary preparations and substances for the treatment of oncological diseases, genetic diseases, fibrosis and degenerative diseases; pharmaceutical preparations for use in targeted pharmaceutical therapies for the treatment of oncological diseases, genetic diseases, fibrosis and degenerative diseases; pharmaceutical preparations and anti-neoplastic products for the treatment of neoplastic diseases; pharmaceutical preparations for the treatment of carcinomas and leukaemias; pharmaceutical preparations for the treatment of central nervous system tumours, glioblastoma, colorectal liver metastasis, squamous cell carcinomas, pancreatic cancer, melanoma, breast cancer hepatocellular carcinoma and metastatic tumours; enhancers or super-enhancers for medical or clinical use; engineered DNA as synthetic super enhancers in gene expression cassettes for medical or clinical use; DNA sequences for medical purposes; pharmaceutical preparations for use in regenerative medicines for treatment of fibrosis, age-associated disorders, senescence, rejuvenation, neurological disease, tissue injury and tissue repair; gene therapy pharmaceuticals for the treatment of neoplastic diseases, central nervous system tumours, glioblastoma, colorectal liver metastasis, squamous cell carcinomas, pancreatic cancer, melanoma, breast cancer hepatocellular carcinoma, leukaemias and metastatic tumours; pharmaceutical preparations being viral vectors namely, adenoviruses, adeno-associated viruses, poxviruses, reoviruses, lentiviruses and herpes simplex viruses; biotechnological preparations for medical use for the treatment of oncological diseases, genetic diseases, fibrosis and degenerative diseases; biological compounds in the nature of engineered DNA elements, viral vectors, enzymes and cytokines for use in the targeted pharmaceutical therapies; protein arrays for medical diagnosis purposes with diagnostic and therapeutic uses; chemical and enzyme preparations for medical or veterinary purposes for the treatment of oncological diseases, genetic diseases, fibrosis and degenerative diseases; reagents and diagnostic substances for use in testing for medical and veterinary purposes; drug delivery agents in the form of dissolvable films, tablets, capsules, powders, emulsions, injections, solutions and suspensions that facilitate the delivery of pharmaceutical preparations; clinical medical reagents; in vitro diagnostic and testing preparations for clinical, medical and medical laboratory use; pharmaceutical preparations in the field of modulating therapeutics; pharmaceutical preparations for the treatment of viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, sexual dysfunction, oncological, hepatological, ophthalmic, otologic, respiratory, neurological, gastrointestinal, pancreatic, nephrologic, musculoskeletal, hormonal, dermatological, psychiatric and immune system related diseases and disorders; biological preparations for the treatment of cancer; biological preparations for use in cell cultures for medical purposes; diagnostic biomarker reagents for medical purposes; cells for medical or clinical use; immune cells being cells for medical use; macromolecules being target antigens for medical use; vaccine preparations; therapeutic vaccines

Classification Information


International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes005, 006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateThursday, April 17, 2025
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

International Class009 - Scientific, nautical, surveying, photographic, cinematographic, optical, weighing, measuring, signalling, checking (supervision), life-saving and teaching apparatus and instruments; apparatus and instruments for conducting, switching, transforming, accumulating, regulating or controlling electricity; apparatus for recording, transmission or reproduction of sound or images; magnetic data carriers, recording discs; automatic vending machines and mechanisms for coin operated apparatus; cash registers, calculating machines, data processing equipment and computers; fire extinguishing apparatus.
US Class Codes021, 023, 026, 036, 038
Class Status Code6 - Active
Class Status DateThursday, April 17, 2025
Primary Code009
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History


Party NameTrogenix Ltd
Party Type10 - Original Applicant
Legal Entity Type24 - NOT AVAILABLE
AddressGB

Trademark Events


Event DateEvent Description
Thursday, April 17, 2025SN ASSIGNED FOR SECT 66A APPL FROM IB
Friday, April 25, 2025NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Friday, April 25, 2025APPLICATION FILING RECEIPT MAILED
Friday, July 11, 2025ASSIGNED TO EXAMINER
Monday, July 21, 2025NON-FINAL ACTION WRITTEN
Tuesday, July 22, 2025NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
Monday, August 25, 2025REFUSAL PROCESSED BY MPU
Monday, August 25, 2025NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
Friday, September 12, 2025REFUSAL PROCESSED BY IB
Saturday, November 29, 2025NEW REPRESENTATIVE AT IB RECEIVED
Monday, February 23, 2026TEAS RESPONSE TO OFFICE ACTION RECEIVED
Monday, February 23, 2026CORRESPONDENCE RECEIVED IN LAW OFFICE
Tuesday, February 24, 2026TEAS/EMAIL CORRESPONDENCE ENTERED
Sunday, April 19, 2026FINAL REFUSAL WRITTEN
Sunday, April 19, 2026FINAL REFUSAL E-MAILED
Sunday, April 19, 2026NOTIFICATION OF FINAL REFUSAL EMAILED